Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression
Promising data from the ATTLAS phase III study indicate a potential new approach for treating patients progressing on TKIs
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future
Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.